Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Carolyn Y. Ho et al.|The Lancet|2020Cited by 1.2k
Clinical Interpretation and Implications of Whole-Genome SequencingFrederick E. Dewey, Thomas Quertermous, Megan E. Grove et al.|JAMA|2014Cited by 458
A public resource facilitating clinical use of genomesMad Price Ball, George M. Church, Joseph V. Thakuria et al.|Proceedings of the National Academy of Sciences|2012Cited by 246
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y. Ho, Eugene Braunwald, Sharlene M. Day et al.|Nature Medicine|2021Cited by 132
A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated DecayTimon Seeger, Joseph C. Wu, Rajani Shrestha et al.|Circulation|2019Cited by 124